Summary: Many primary human tumors and tumor cell lines highly express human L-type amino acid transporter 1 (hLAT1); cancerous cells in vivo are strongly linked to LAT1 expression. Synthetic chemistry and in vitro screening efforts have afforded a variety of novel and highly hLAT1 selective compounds, such as JPH203 1. In a recent report, we demonstrated that 1 has potent in vitro and in vivo activity. JPH203 was intravenously administered to produce significant growth inhibition against HT-29 tumors transplanted in nude mice. The current work develops a robust LC/MS-MS method to monitor 1 and its major Phase II metabolite N-acetyl-JPH203 2 from biological samples. We have conducted in vitro and in vivo experiments and the major scientific findings are: i) the major route of biotransformation of 1 is Phase II metabolism to produce 2; ii) metabolite 2 is formed in various organs/tissues (i.e. blood, liver, kidney); and iii) as dogs, which are deficient in NAT genes, do not produce 2, the dog will not be an appropriate toxicological model to evaluate 1.
Introduction
System L transporters transport branched-chain AAs ¤i.e. valine, isoleucine, and leucine¥, and neutral AAs with limited bulky aromatic side chains ¤i.e. phenylalanine and tyrosine¥, into cells. 1¥ Various L-type amino acid transporters, such as LAT1, 2¥ LAT2, 3¥ LAT3, 4¥ and LAT4 5¥ have been identified as system L transporters. LAT1 and LAT3 have been shown to be selectively expressed in tumor cells.
4,6¥ Many primary human tumors and tumor cell lines, such as uterine cervical carcinoma cells ¤HeLa¥, bladder carcinoma cells ¤T24¥, and lung small-cell carcinoma cells ¤RERF-LC-MA¥ highly express LAT1. 4¥ In the late 1990s, we hypothesized that hLAT1 selective compounds are useful therapeutic cancer agents. In 1998, LAT1 expression cloning was first reported. 2¥ In 2002, we described fundamental insights into the mechanisms of rat LAT1 substrate recognition. 7¥ The in vitro data supported the notion that small aromatic amino acids require the free carboxyl ¤i.e. not an ester¥ and amino group ¤i.e. no alkyl groups on the amine¥ in order to be an LAT1 substrate. 7¥ Beginning in 2002, extensive medicinal chemistry efforts in our laboratories have generated a variety of LAT1, LAT2, and LAT1/LAT2 selective compounds. Recently, we reported the establishment of mammalian cell lines expressing hLAT1 or hLAT2 8¥ and referred to as S2-hLAT1 and S2-hLAT2, respectively. These LAT expressing cell lines provide us with a robust in vitro cell-based tool to evaluate the interaction of novel compounds with hLAT1 and hLAT2 transporter proteins. Synthetic chemistry and subsequent in vitro screening efforts have identified novel compounds, such as JPH203 ¤1; previously known as KYT-0353; Fig. 1¥ , which have very profound ¤low IC 50 ¥ and selective in vitro hLAT1 inhibition activity. Recently, we presented a mouse in vivo proof-of-concept experiment; intravenous ¤i.v.¥ administration of 1 displayed significant growth inhibition against HT-29 tumors transplanted into nude mice. 9¥ The aim of the current work is to provide the first report of an LC/MS-MS bio-analytical pharmacokinetic ¤BAPK¥ method to monitor 1 from in vivo samples. Herein, we summarize: i¥ in vitro metabolism studies demonstrating species differences; ii¥ the development of an LC/MS-MS method to monitor 1 and its major metabolite N-acetyl¤NAc¥-JPH203 2, and iii¥ rat intravenous ¤i.v.¥ PK data via the developed LC/MS-MS method.
Methods
Materials: Subcellular liver microsomal fractions CD-1 mouse ¤male, Lot #0410161, pool of 1000¥, SpragueDawley rat ¤male, Lot #0510153; pool of 431¥, beagle dog ¤male, Lot #0510225, pool of 5¥, cynomologous monkey ¤male, Lot #0510264, pool of 14¥, and human ¤male, Lot #0510007, pool of 10¥, and S9: Sprague-Dawley rat intestinal S9 ¤male, Lot # 0810089, pool of 249¥, human intestinal S9 ¤mixed gender, Lot # 0710351, pool of 18¥, and Sprague-Dawley rat kidney S9 ¤male, Lot # 0510096, pool of 146¥ were acquired from Xenotech LLC ¤Kansas City, KS¥. The S9 fractions from ICR/CD-1 mouse ¤male, Lot #VLH, pool of 30¥, Sprague-Dawley rat ¤male, Lot #TNI, pool of 30¥, beagle dog ¤male, Lot #LQU, pool of 5¥, cynomologous monkey ¤male, Lot #NAE, pool of 5¥, and human ¤mixed gender, Lot #RTO, pool of 5¥ were purchased from InVitro Technologies, Inc. ¤Baltimore, MD¥. HPLC grade water, acetonitrile, methanol, ethanol, isopropyl alcohol, ammonium acetate, formic acid, DMSO, KH 2 PO 4 , UDP-glucuronic acid ¤UDPGA¥, NADH, NADPH, acetyl coenzyme A ¤acetyl-CoA¥ sodium salt hydrate, glutathione ¤GSH¥, EDTA, MgCl 2 , alamethicin, tamoxifen, and verapamil hydrochloride were obtained from Sigma-Aldrich Chemical Co. ¤St. Louis, MO¥. JPH203 HCl salt ¤purity h 99%¥ was obtained from J-Pharma ¤Tokyo, Japan¥.
In vitro metabolism of JPH203 in microsomes: Test compounds were freshly prepared as stock solutions in DMSO ¤10.0 mM¥. Immediately prior to an experiment, an aqueous drug solution ¤10.0 µM¥ was prepared. To probe in vitro hepatic metabolism, liver microsomal incubations were conducted at 37.0 + 0.1ôC and included ¤final concentration¥ 0.20 mg/mL microsomal protein with various co-factors and/or reagents such as: NADPH ¤1.0 mM, cofactor for monooxygenases, e.g., cytochrome P450¥, UDPGA ¤4.0 mM, cofactor for glucuronidation; e.g. UGTs¥, alamethicin ¤60 µg/mg protein¥ and 1.0 µM test compound ¤DMSO : 0.2%, total v/v¥. Incubations consisted of phosphate buffer ¤100 mM; pH 7.4¥, MgCl 2 ¤5.0 mM¥, and EDTA ¤1.0 mM¥. Incubations were performed as follows: i¥ a mixture of phosphate buffer, MgCl 2 , NADPH, UDPGA, alamethicin, and liver microsomal protein was pre-incubated at 37 + 0.1ôC for 10 min; ii¥ incubations were initiated by test compound addition and mixing ¤1.0 µM final¥, also preincubated at 37 + 0.1ôC. After initiation ¤0.5 min¥, 10, 20, and 30 min, an incubate sample was removed and added to two volumes of quench solution ¤cold acetonitrile¥. The resulting samples were vortexed ¤>5 s¥ and centrifuged ¤3,000 rpm, 10 min, 10ôC; Labofuge 400R Centrifuge; VWR, West Chester, PA¥. Samples were immediately analyzed by LC/MS-MS. Additional control incubations for all test compounds were conducted without microsomal protein and terminated at 30 s and 30 min.
In vitro metabolism of JPH203 in S9 incubations: Immediately prior to an experiment, an aqueous drug solution ¤10.0 µM¥ was prepared. S9 incubations were conducted at 37.0 + 0.1ôC and consisted of phosphate buffer ¤pH 7.4, 100 mM¥, MgCl 2 ¤5.0 mM¥, EDTA ¤1.0 mM¥, NADH ¤1.0 mM¥, acetyl-CoA ¤0.85 mM¥, S9 protein ¤0.20 mg/mL¥, and substrate ¤1.0 µM; DSMO : 0.1%¥. Incubations were initiated by substrate addition and terminated at various times ¤i.e. 1, 5, 10, 15, 20, and 30 min¥ via aliquot removal and mixing with three volumes of cold acetonitrile. Control incubations ¤30 s and 30 min¥ were also conducted but without S9 protein.
In vivo experimental and sample collection: The in-life portion was conducted at East Tennessee State University®Quillen College of Medicine in an AAALAC accredited facility. All procedures were reviewed and approved by the ETSU Committee on Animal Care. Male Sprague-Dawley rats were purchased from Harlan World Headquarters ¤Indianapolis, IN¥. Animals were housed in groups of three at 22.2 + 1.1ôC and 55 + 15% humidity with 12 h dark light cycles. Dosing occurred 2.0®2.5 h after the beginning of a light cycle. All animals had access to water, and were fasted 14®16 h prior to dosing in cages with bedding; food was returned 4 h post-dose.
Fasted animals ¤251 + 10 g¥ were dosed via the ophthalmic venous plexus ¤orbital sinus¥ using a 1.0 mL disposable syringe with a 27G needle. Immediately prior to dosing, dose solution was prepared by putting 100 µL of a 100 mM stock JPH203 solution ¤DMSO¥ into water ¤4,900 µL¥ containing DMSO ¤100 µL¥; hence, a 1.96 mM dose solution contained DMSO ¤3.9%¥. Using tail-vein collection ¤i.e. the anterior portion was transected, 2®3 mm¥, blood samples ¤125 µL¥ were collected using mini-capillary blood collection tubes containing EDTA di-potassium salt ¤SAFE-T-FILL ¬ ; RAM Scientific Inc., Yonkers, NY¥. Immediately after filling, individual sample tubes were mixed and stored on dry ice and kept frozen ¤%80 + 10ôC¥ until sample preparation and subsequent LC/MS-MS analysis.
LC/MS-MS analysis: An Applied Biosystems Sciex 4000 ¬ ¤Applied Biosystems; Foster City, CA¥ equipped with a Shimadzu HPLC ¤Shimadzu Scientific Instruments, Inc.; Columbia, MD¥ and LEAP auto-sampler ¤LEAP Technologies; Carrboro, NC¥ was used. Liquid chromatography employed an Agilent Technologies, Zorbax extended-C18 50 ' 4.6 mm, 5 µm column at 40ôC with a flow-rate of 0.4 mL/min. The mobile phase consisted of A: 10 mM ammonium acetate, 0.1% formic acid in water, and B: 50:50 acetonitrile:methanol. Compounds were monitored via electrospray ionization positive ion mode ¤ESI¦¥ using the following conditions: i¥ an ion-spray voltage of 5,500 V; ii¥ temperature, 450ôC; iii¥ curtain gas ¤CUR¥ and collisionally activated dissociation ¤CAD¥ gas were nitrogen; iv¥ CAD gas was set at medium; v¥ entrance potential was set at 10.0 V; vi¥ unless specifically denoted, quadruple one ¤Q1¥ and ¤Q3¥ were set on Unit resolution; vii¥ dwell time was set at 200 ms; and viii¥ declustering potential ¤DP¥, collision energy ¤CE¥, and collision cell exit potential ¤CXP¥ are voltages ¤V¥. Compound settings were: i¥ verapamil: 455.3 G 165.2 m/z, GS1 ¤15¥, GS2 ¤10¥, DP ¤86¥, CE ¤41¥, and CXP ¤6¥; ii¥ JPH203 1 ¤472.0 G 224.2 m/z¥ and NAc-JPH203 2 ¤514.0 G 266.1 m/z¥ were GS1 ¤20¥, GS2 ¤20¥, DP ¤46¥, CE ¤43¥, CXP ¤4¥ and Q3 set on open; tamoxifen ¤IS¥ was DP © 91, CE © 47, CXP © 12 and monitored as 372.0 G 72.0 m/z. Samples ¤10 µL¥ were analyzed by LC/MS-MS. The chromatography method used for verapamil, was 95% A for 1.0 min, brought to 95% B at 3.0 min and held for 2.2 min, brought back to 95% A at 5.6 min and held for 1.4 min ¤7.0 min total run time¥. The chromatography method used for 1 and 2 was 95% A for 1.0 min, brought to 95% B at 6.0 min and held for 3.5 min, brought back to 95% A at 10.5 min and held for 1.5 min ¤12.0 min total run time¥.
Rat blood extraction, calibration and quality control samples:
Rat blood was collected ¤tubes containing EDTA¥ from fed ¤n © 6¥ and fasted ¤n © 6¥ control animals via inferior vena cava bleeding. Standard curve ¤SC¥ and quality control ¤QC¥ solutions of 1 were separately prepared by adding aqueous solutions ¤50 µL¥ to cold blood ¤950 µL¥ and mixed. SC and QC samples were immediately frozen ¤%80 + 10ôC¥. An extraction solution containing an internal standard ¤IS¥¯40.0 nM tamoxifenw as prepared in a volumetric flask ¤500 mL¥ containing 4:1 ¤1:1 acetonitrile:methanol¥ and water ¤v/v¥. In individual animal sets, PK, SC, and/or QC sample tubes were removed from the freezer ¤%80 + 10ôC¥ and allowed to warm at ambient temperature ¤10 min¥. Tubes were vortexed ¤3®5 s¥ and extraction solution ¤250 µL¥ added, vortex mixed ¤3®5 s¥, and sonicated ¤5.0 min, Branson 2510 Ultrasonic cleaner; Danbury, CT¥. Tubes were centrifuged ¤13,200 rpm; 5.0 min¥ using an Eppendorf minispin centrifuge ¤Hamburg, Germany¥. Supernatants ¤275 + 5 µL¥ were transferred into individual wells of a 96-well plate. The 96-well plate was sealed and centrifuged ¤3,000 rpm, 10 min, 10ôC; Labofuge 400R Centrifuge¥. The 96-well plate was placed into the LEAP auto-sampler cool-stack ¤6.0 + 0.1ôC¥ and samples immediately analyzed via LC/MS-MS. In addition, SC and QC sample stability was probed in two ways: i¥ spiked blood samples were exposed to multiple freeze-thaw cycles; and ii¥ solvent extracted SC and QC samples were kept in the LEAP auto-sampler cool-stack ¤6.0 + 0.1ôC¥ and periodically monitored. Analyst 1.4.2 was used for data acquisition. Prism 4.02 ¤GraphPad Software, Inc.; San Diego, CA¥ was used for data analysis, graphing, and statistical analysis. As with the in vitro samples, extracted PK samples ¤10 µL¥ were injected onto a Zorbax extended-C18 50 ' 4.6 mm, 5 µm 80 ! column ¤Agilent Technologies, Santa Clara, CA¥. The column temperature was maintained at 40 + 1ôC. Between PK samples, the auto-sampler was washed ¤four times¥ with a 1:1:1:1 mixture of ACN:MeOH:IPA:water containing 0.1% formic acid.
10¥
JPH203 in vitro plasma:red blood cell concentration determination: To probe intrinsic plasma/red blood cell concentration of 1, control rat blood was collected from male rats ¤n © 8¥ and pooled. While still warm, blood was transferred into four vials ¤9.9 mL per vial¥ and subsequently spiked with 100 µL of aqueous solutions of 1, mixed, and incubated with shaking at 37.0 + 0.1ôC ¤15 min¥. The additions afforded theoretical blood concentrations of 1.00, 0.50, 0.10, and 0.05 µM. After 15 min, the vials were cooled in an ice bath ¤5.0 min¥ and centrifuged ¤15,000 rpm; 25 min¥. The red blood cells and plasma were separated. In triplicate, samples ¤250 µL¥ were taken, frozen ¤%80 + 10ôC¥ for 24 h, thawed, and subsequently extracted with extraction solution ¤500 µL¥ and processed as previously described.
In vitro JPH203 blood stability study: Rat blood was collected from control male rats ¤n © 8¥ and pooled. While still warm, blood ¤7.92 mL¥ was transferred into a vial and subsequently spiked with aqueous 1 ¤1,000 µM; 80 µL¥, mixed, and incubated ¤37ôC¥. This afforded a theoretical blood concentration of 10.0 µM. At 1.0, 10, 20, 30, 45 and 60 min, samples ¤250 µL¥ in triplicate were taken, frozen ¤%80 + 10ôC¥, thawed, and subsequently extracted with extraction solution ¤500 µL¥ and processed as previously described.
Data analysis and statistical methods: The in vitro microsomal and S9 subcellular fraction data was analyzed and expressed as percent disappearance of parent relative to the 30 s time sample. The in vitro T 1/2 value was obtained from the slope of the non-linear regression via the percentage remaining versus incubation time relationship ¤%k¥ as follows: in vitro T 1/2 © %0.693/k. The results were used to calculate in vitro intrinsic clearance ¤CL int , in units of µL/min/mg protein¥ similar to previously described methods.
11¥ Pharmacokinetic data were computed using a non-compartmental analysis model via linear trapezoidal rule using the software program WinNonlin ¬ ¤V01.5¥.
Results

In vitro metabolism studies:
Liver microsomal incubations were conducted in the presence of NADPH and UDPGA, co-factors required for CYP oxidation ¤Phase I biotransformation¥ and glucuronidation ¤Phase II biotransformation¥, respectively. As summarized in Table 1 , JPH203 1 was metabolically stable in mouse, rat, dog, monkey and human liver microsomal incubations ¤Table 1¥. Furthermore, illustrating that we were in fact using viable liver microsomes, a variety of well-known drugs were also tested. The verapamil data, an example of a compound well known to undergo CYP catalyzed metabolism, has been included ¤Table 1¥.
12¥ Hence, there was no apparent evidence that 1 readily underwent CYP oxidative or glucuronidation in vitro biotransformation. We then probed cytosolic metabolism pathways and used S9 sub-cellular fractions in the presence and absence of various co-factors ¤e.g. NADH, GSH, acetyl-CoA, etc.¥. As summarized in Table 2 , we observed N-acetyltransferase ¤NAT¥ Phase II metabolism of 1 ¤Fig. 1¥. As per the calculated S9 CL int values, 1 was found to readily biotransform to NAc-JPH203 2 in rat, monkey and human S9 liver incubates. A trace amount of 2 was observed in mouse incubates while no formation was detected in dog incubates. 13¥ These data provide an in vitro species biotransformation rate trend of rat h monkey hh human hh mouse h dog. As illustrated in the chromatogram ¤Fig. 2¥, 1 and 2 were separated by HPLC and detected via MS-MS methods. Furthermore, we also probed rat intestine, rat kidney, and human intestine in vitro metabolism. Human intestine metabolism was faster than rat intestine, and rat kidney S9 also catalyzed the metabolism of 1 ¤Table 2¥.
Bio-analytical pharmacokinetic summary: As illustrated in Figure 2 , the LC/MS-MS method afforded average retention times ¤t R ¥ of 5.4, 5.7, and 6.4 min for 1, 2, and tamoxifen ¤IS¥, respectively. To avoid endogenous lipid matrix ionization effects with 1 or 2, in-source multiple reaction monitoring ¤IS-MRM¥ was probed during method development. 10¥ SCs were individually prepared from fed ¤n © 4¥ and fasted ¤n © 4¥ blood and displayed no significant difference in analytical response; however, cold blood was required to avoid in situ metabolism ¤discussed below¥. SC data ¤i.e. fed and fasted data were pooled; n © 8¥ was fitted to a 1/x 2 weighted linear regression using ten SC concentrations ¤1.5®3,000 ng/mL¥. The limit-of-quantification ¤LOQ¥ from extracted rat blood¯defined here as the level at which LC/MS-MS detection precision was g20%w as determined to be >3.8 ng/mL. Limit-of-detection ¤LOD¥ from rat blood was >1.5 ng/mL; the correlation coefficient ¤R 2 ¥ was 0.9994. We also utilized QC samples ¤1 at 5.0, 17.0, 44.0 and 240 ng/mL¥ during PK sample analysis. During method development, we did not observe stability issues associated with 1 in rat blood until three freeze-thaw cycles. Furthermore, extracted samples kept in the cool-stack ¤6.0 + 0.1ôC¥ showed no evidence of analyte detection loss within 48 h; however, after 4®5 days, >10® 20% sensitivity loss was observed and thus sample process and analysis should be conducted accordingly. Furthermore, one should minimize freeze-thaw cycles and analyze extracted samples within 24 h ¤i.e. standard, good laboratory practice¥. Lastly, the in vitro S9 metabolism screening experiments demonstrated a similar analytical response in loss of 1 with concurrent formation of 2 ¤i.e. via area under the curve comparison¥.
In vitro rat blood stability study: To probe intrinsic plasma/RBC distribution of 1, control rat blood was spiked with 1 and incubated ¤37ôC; 15 min¥. Compound 1 had a higher propensity to be retained in the plasma fraction. Furthermore, these experiments summarized in illustrate that warm rat blood has the ability to convert 1 to 2 in vitro; this is the reason why QC and SC must be prepared using ice-cold rat blood. From these data, metabolite 2 has a much higher propensity to reside with the plasma fraction. The fact that 1 is readily taken up into RBCs and subsequently metabolized to 2 illustrates the importance of collecting blood and extracting whole blood; if one only collects and analyzes plasma then one may not obtain the same concentration conclusions for 1 ¤i.e. ng/mL data¥. To further illustrate these observations, 1 in fresh rat blood was monitored ¤37ôC; 60 min¥. Compound 1 displayed a linear time-dependent decrease with a linear time-dependent increase in 2. These data further confirm the observed in vitro metabolism; hence, rat erythrocytes also possess NAT 14,15¥ and metabolize 1 to 2. JPH203 intravenous study in male SpragueDawley rats: Sprague-Dawley rat i.v. PK experiments were conducted. As presented in Figures 3, 1 was dosed ¤0.9®1.0 mg/kg¥ to fasted rats ¤n © 4¥ and blood time points collected post-dose ¤5 min¥, 7, 17, 33, 47, 57, 93, 119, JPH203 (1) NAc-JPH203 (2) Fig. 2 . Representative chromatograph of JPH203 1, NAc-JPH203 2 and tamoxifen as an internal standard (IS) The average AUC 0®W of 1 computed via noncompartmental bolus IV administration was 2,343 ng&min/ mL with an extrapolated C max of 27.9 ng/mL and a half-life Lambda Z of 80.3 min. Metabolite 2 was computed to have an average AUC 0®W of 3,397 ng&min/mL, a C max of 17.2 ng/mL, a T max of 47.2 min, and a half-life Lambda Z of 76.8 min ¤i.e. using the last 3 time-points¥. After >3 h postdose, blood levels of 1 were below-the-limit-of-quantification ¤BLOQ; Fig. 3¥ .
Discussion
The major route of in vitro and in vivo biotransformation of JPH203 1 is Phase II metabolism to afford NAc-JPH203 2.
The results are interesting because we had speculated that the 2-phenylbenzoªd«oxazole functionality ¤Southern region¥ within 1 ¤Fig. 1¥ would be metabolized by CYPs. Thus, it was advantageous when 1 displayed such a sound metabolic stability in mouse, rat, dog, monkey and human liver microsomal incubations ¤Table 1¥. The importance of low to no CYP catalyzed biotransformation of 1 is very profound and critical for the development of this chemical template. From our structure-activity relationship ¤SAR¥ studies ¤unpublished data¥, we know that para-hydroxylation of analog 1 affords significant loss of LAT1/LAT2 selectivity and thus would not result in a clinically useful drug candidate.
When the cytosolic metabolism pathways were probed, S9 sub-cellular fractions in the presence and absence of various co-factors ¤e.g. NADH, GSH, acetyl-CoA, etc.¥, we observed N-acetyltransferase ¤NAT¥ Phase II metabolism of 1 ¤Table 2¥. As per the calculated S9 CL int values, 1 was found to readily biotransform to NAc-JPH203 2 in rat, monkey and human S9 liver incubates. A trace amount of 2 was observed in mouse incubates while no formation was detected in dog incubates. These data provide an in vitro species biotransformation rate trend of rat h monkey h human hh mouse hhh dog. As illustrated in the chromatogram ¤Fig. 2¥, 1 ¤5.5 min¥ and 2 ¤5.7 min¥ were separated by HPLC and detected via MS-MS methods. The fact that NAT catalyzed Phase II metabolism was not observed in dog incubates was consistent with the fact that dogs are deficient in NAT genes. 13¥ Therefore, dog liver S9 should not convert 1 to 2; blank experiments ¤i.e. acetyl-CoA without S9 protein¥ showed no conversion. We also probed rat intestine, rat kidney, and human intestine in vitro metabolism. Human intestine metabolism was faster than rat intestine, and rat kidney S9 also catalyzed the metabolism of 1 ¤Table 2¥.
As previously reported, 9¥ 1 has potent and LAT1 selective 14 C-leucine uptake inhibition ¤i.e. 140 nM via the S2-LAT1 cell line¥. The current in vitro and in vivo metabolism studies of 1 warrant a general discussion regarding tissue distribution and elimination. While the extensive SAR has not yet been published, we know that LAT1 tolerates minor modification in the Northern region of the 2-phenylbenzoªd«oxazole moiety ¤Fig. 1¥ and does not profoundly alter LAT1/LAT2 selectivity. Metabolite 2 has been determined to be active and LAT1 selective; in the S2-LAT1 screen, 2 was approximately a 4-fold less potent inhibitor ¤higher IC 50 ¥ than 1 ¤i.e. >540 nM¥. We also know that 1 has low intrinsic aqueous solubility ¤:1.0 mg/mL in HPLC grade water, pH 6.1, 21.5ôC¥ and in the Caco-2 monolayer assay¯using previously described methods at 10 µM 16¥¯1 showed low apical-to-basolateral permeability ¤0.61 + 0.07 ' 10 %6 cm/s¥ but moderate basolateral-toapical permeability ¤32.6 + 0.5 ' 10 %6 cm/s¥. The presence of cyclosporine A ¤CSA¥ in this in vitro permeability assay did not statistically modify the results and supports the notion that 1 is not a P-glycoprotein ¤Pgp¥ substrate. Thus, as we attempt to develop 1 into an orally acceptable cancer drug, not just for intravenous administration, formulation development of 1 ¤i.e. incorporating solubility enhancers¥ is ongoing. Also confirmed by analyzing organ homogenates, we know that the distribution of 1 after an intravenous dose displays very fast distribution from the blood-stream ¤i.e. high hepatic extraction¥ and becomes readily sequestered in the liver and kidney. Metabolism of 1 to give 2 predominately occurs via the liver, but also occurs in RBCs and kidneys. As summarized in Table 3 , 1 appears to readily permeate ¤e.g. 30®40%¥ into RBCs. Lastly, 1 and 2 have two main in vivo routes of distribution/elimination. The first occurs via fast distribution and elimination to the liver and kidneys, while the second occurs via biliary excretion and elimination into the GI tract. These experimental observations support the notion that 1 may be best suited as a therapeutic agent for the treatment of colon, liver, and kidney related cancers; LAT1 in not present in these organs of healthy individuals. As 1 does not readily distribute into the brain, we conclude that it will not be an ideal head-and-neck cancer therapeutic agent, but that does not exclude the possibility of developing organ-specific pro-drug/targeting approaches. Hence, additional research studies are warranted.
In summary, the major findings from these studies are: i¥ an LC/MS-MS bio-analytical pharmacokinetic ¤BAPK¥ method for 1 and 2 has been developed; ii¥ the major metabolic route formed in vitro and in vivo ¤rat¥ was Phase II metabolism of 1 to form 2; iii¥ metabolite 2 forms in various organs/tissues ¤i.e. blood, liver, kidney¥ as the predominate metabolite; and iv¥ because dogs are deficient in NAT genes, 13¥ the dog will not be an appropriate toxicological model to evaluate 1; rather, the rat and monkey appear to be more appropriate species to conduct pre-clinical toxicological evaluations.
